Tin tức & Cập nhật
Xem bài viết Niệu khoa
Xem

Erdafitinib prevails in bladder cancer with select FGFRalt
The oral selective pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib demonstrated a survival advantage over chemotherapy, extending multiple efficacy endpoints in individuals with advanced or metastatic urothelial carcinoma (mUC) with FGFR alterations (FGFRalt) after previous anti-PD-(L)1 treatment, findings from the confirmatory phase III THOR trial have shown.

Does extended lymph node sampling increase complications?
Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.

50-percent decrease in severity a meaningful endpoint in chronic pelvic pain
A clinically meaningful endpoint for future therapeutic trials in urological chronic pelvic pain syndrome is a decrease of 30‒50 percent in pelvic pain severity, suggests a study. Clinically significant differences for urinary symptom severity are more appropriately defined separately for males and females.





